Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing SchedulesRanjana H. Advani, Daniel C. Adelman, David S. Mendelson et al.|Clinical Cancer Research|2010Cited by 45
Pharmacokinetics of a Recombinant Modified Amino Terminal Fragment of Bactericidal/Permeability‐Increasing Protein (rBPI<sub>21</sub>) in Healthy VolunteersRobert J. Bauer, Stephen F. Carroll, Nancy Wedel et al.|The Journal of Clinical Pharmacology|1999Cited by 8